Characterization of psoriasis patients in special body areas: real-world evidence from the Chinese Psoriasis Standardized Diagnosis and Treatment Center

被引:0
|
作者
Gao, Yuge [1 ,2 ]
Li, Chao [1 ]
Tong, Meng [1 ]
Hu, Yizhou [3 ]
Li, Yuzhen [1 ]
机构
[1] Harbin Med Univ, Affiliated Hosp 2, Dept Dermatol, Harbin, Peoples R China
[2] Natl Clin Res Ctr Skin & Immune Dis, Beijing, Peoples R China
[3] Karolinska Inst, Dept Med Biochem & Biophys, Stockholm, Sweden
基金
国家重点研发计划;
关键词
Psoriasis; special body areas; real-world evidence; DISEASES; BURDEN; SCALE;
D O I
10.1080/09546634.2024.2337264
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
BackgroundWhile extensive research has provided a wealth of information on psoriasis in general, there remains a critical gap in understanding the unique characteristics of psoriasis in special body areas, such as the scalp, nails, palms, and genitals.ObjectiveTo investigate the characterization and treatment of psoriasis patients in special body areas.MethodsThe study was a retrospective analysis of patients with psoriasis enrolled in the Psoriasis Standardized Diagnosis and Treatment Center Project between January 2020 and September 2021.ResultsThe study encompassed 346 patients, 81% of them had psoriasis in at least two special body areas, with the nails as the most common area. Patients with genital psoriasis reported higher Dermatology Life Quality Index (DLQI) scores. A higher propensity for scalp and palmoplantar psoriasis was noted in patients with genital psoriasis. The proportion of patients treated with biologics rose, as the number of specific areas involved increased.ConclusionsPatients with genital psoriasis are more likely to have scalp and palmoplantar psoriasis. This study highlights the significant escalation in the proportion of biologics when the involvement of special body areas was >= 2.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Prospective cohort study of psoriatic arthritis risk in patients with psoriasis in a real-world psoriasis registry
    Ogdie, Alexis
    Harrison, Ryan W.
    McLean, Robert R.
    Lin, Tin-chi
    Lebwohl, Mark
    Strober, Bruce E.
    Zhuo, Joe
    Patel, Vardhaman
    Mease, Philip J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2022, 87 (06) : 1303 - 1311
  • [32] Effectiveness and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis in real-world practice
    Zhou, Jian
    Yuan, Yuan
    Liu, Yanhua
    Chu, Mengyang
    Liu, Huan
    Liu, Qian
    Wang, Rui
    Shao, Shuai
    Wang, Gang
    Yu, Chen
    EXPERIMENTAL DERMATOLOGY, 2024, 33 (01)
  • [33] Guselkumab Treatment Outcomes and Persistence in a Nationwide Real-world Cohort of Patients with Plaque Psoriasis
    Malkonen, Tarja
    Nuutinen, Pauliina
    Hallinen, Taru
    Soini, Erkki
    Nissinen, Riikka
    Wennerstom, Christina
    Rantanen, Tapio
    Hagman, Johanna H.
    Harvima, Rauno
    Hook-Nikanne, Johanna
    Ilves, Tiina
    Lintu, Paivi
    Malanin, Ken
    Soramaki, Iina
    Tasanen, Kaisa
    Teho, Arja
    Vahavihu, Katja
    Italinna, Sari
    Leinonen, Pekka
    Sarajarvi, Piia
    Huilaja, Laura
    Pasternack, Rafael
    ACTA DERMATO-VENEREOLOGICA, 2022, 102
  • [34] Comparison of real-world treatment patterns among patients with psoriasis prescribed ixekizumab or secukinumab
    Blauvelt, Andrew
    Shi, Nianwen
    Burge, Russel
    Malatestinic, William N.
    Lin, Chen-Yen
    Lew, Carolyn R.
    Zimmerman, Nicole M.
    Goldblum, Orin M.
    Zhu, Baojin
    Murage, Mwangi J.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 82 (04) : 927 - 935
  • [35] Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab
    Blauvelt, Andrew
    Shi, Nianwen
    Burge, Russel
    Malatestinic, William N.
    Lin, Chen-Yen
    Lew, Carolyn R.
    Zimmerman, Nicole M.
    Goldblum, Orin M.
    Zhu, Baojin
    Murage, Mwangi J.
    PATIENT PREFERENCE AND ADHERENCE, 2020, 14 : 517 - 527
  • [36] Real-world evidence on time to relapse of plaque psoriasis after discontinuation of biologic treatment in Poland
    Owczarek, Witold
    Dzik, Maciej
    Narbutt, Joanna
    Walecka, Irena
    Kowalczyk, Marta
    DERMATOLOGIC THERAPY, 2021, 34 (05)
  • [37] Ixekizumab for the treatment of the patients with moderate to severe plaque psoriasis: Clinical data from a real-world experience
    Gonulal, Melis
    Altunay, Ilknur Kivanc
    Dogan, Sinan
    Turkmen, Meltem
    Balci, Didem Didar
    Ozturkcan, Serap
    DERMATOLOGIC THERAPY, 2022, 35 (12)
  • [38] Effectiveness of Ixekizumab in Chinese Patients with Moderate-Severe Plaque Psoriasis with Special Area Involvement: Subanalysis of a Prospective, Multicenter, Observational Real-World Study
    Li, Ying
    Lv, Chengzhi
    Dang, Lin
    Lin, Bingjiang
    Tao, Juan
    Zhang, Chunlei
    Zhou, Xiaoyong
    Ma, Han
    Lu, Yi
    Chen, Rong
    Li, Jinnan
    Dou, Guanshen
    Liang, Yunsheng
    Liang, Yanhua
    Shi, Yuling
    DERMATOLOGY AND THERAPY, 2024, 14 (04) : 907 - 918
  • [39] Effectiveness and Safety of Etanercept in Paediatric Patients with Plaque-Type Psoriasis: Real-World Evidence
    Narbutt, Joanna
    Jakubczak, Zofia
    Wasiewicz-Ciach, Paulina
    Wojtania, Joanna
    Krupa, Katarzyna
    Sobolewska-Sztychny, Dorota
    Ciazynska, Magdalena
    Kolt-Kaminska, Marta
    Reich, Adam
    Skibinska, Malgorzata
    Lesiak, Aleksandra
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (16)
  • [40] Tildrakizumab Treatment for Psoriasis in Real-world Practice: An Analysis from the Swiss Registry (SDNTT)
    Maul, Julia-Tatjana
    Melike, A. K.
    Cerminara, Sara E.
    Steinmann, Simona
    Goessinger, Elisabeth, V
    Darzina, Anna
    Monferrer, Iker Oyanguren
    Micheroli, Raphael
    Kokolakis, Georgios
    Roider, Elisabeth
    Oestereich, Felix
    Mateu, Eva
    Burlando, Martina
    Navarini, Alexander A.
    Kundig, Thomas
    Maul, Lara Valeska
    ACTA DERMATO-VENEREOLOGICA, 2024, 104